|
|
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5446-5456.
Prepublished online as a Blood First Edition Paper on January 23, 2008; DOI 10.1182/blood-2007-06-093906.
 Previous Article | Next Article 
Submitted June 4, 2007
Accepted December 15, 2007
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines
Michael Hallek*, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillaume Dighiero, Hartmut Dohner, Peter Hillmen, Michael J. Keating, Emili Montserrat, Kanti R. Rai, and Thomas J. Kipps
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Lombardi Cancer Center, Georgetown University Hospital, Washington, DC, United States
Academic Department of Haematology & Cytogenetics, Institute of Cancer Research, London, United Kingdom
Department of Hematology and Oncology, Universita Vita-Salute San Raffaele, Milano, Italy
Institute Pasteur, Montevideo, Uruguay
Department of Internal Medicine - Hematology, University Hospital of Ulm, Ulm, Germany
Pinderfields Hospital, Wakefield, United Kingdom
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Hematology, Hospital Clinic, Barcelona, Spain
Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, NY, United States
Department of Medicine, University of California-San Diego, La Jolla, CA, United States
* Corresponding author; email: michael.hallek{at}uni-koeln.de.
In 1988 and 1996, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL to facilitate comparisons between different treatments and to establish definitions that could be used in scientific studies on the biology of this disease.1,2 The Food and Drug Administration (FDA) also adopted these guidelines in their evaluation and approval of new drugs. During the last decade, considerable progress has been made in defining new prognostic markers, diagnostic parameters and treatment options, prompting the IWCLL-sponsored Working Group to revise the 1996 criteria.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Z. Rassenti, S. Jain, M. J. Keating, W. G. Wierda, M. R. Grever, J. C. Byrd, N. E. Kay, J. R. Brown, J. G. Gribben, D. S. Neuberg, et al.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Tam, S. O'Brien, W. Wierda, H. Kantarjian, S. Wen, K.-A. Do, D. A. Thomas, J. Cortes, S. Lerner, and M. J. Keating
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Blood,
August 15, 2008;
112(4):
975 - 980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al.
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL
Blood,
July 15, 2008;
112(2):
394 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
